Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26.

2.

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.

Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA.

Nephrol Dial Transplant. 2017 May 1;32(5):870-879. doi: 10.1093/ndt/gfw042.

PMID:
27190329
3.

Block randomized trial evidencing lower mortality with sevelamer compared with calcium phosphate binder in incident dialysis patients.

Mansour J, Shahapuni I, El Esper N, Fournier A.

Kidney Int. 2008 Feb;73(4):510. doi: 10.1038/sj.ki.5002752. No abstract available.

4.

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.

Monge M, Shahapuni I, Oprisiu R, El Esper N, Morinière P, Massy Z, Choukroun G, Fournier A.

Nat Clin Pract Nephrol. 2006 Jun;2(6):326-36.

PMID:
16932454
5.

How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?

Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.

Semin Dial. 2005 May-Jun;18(3):226-38. Review.

PMID:
15934970
6.

[Randomized trials in the prevention of recurrent calcium oxalate stones].

Presne C, Monge M, Bataille P, el Esper N, Choukroun G, Fournier A.

Nephrologie. 2003;24(6):303-7. Review. French.

PMID:
14584297
7.

Bone mineral density directly correlates with elevated serum leptin in haemodialysis patients.

Ghazali A, Grados F, Oprisiu R, Bunea D, Morinière P, El Esper N, El Esper I, Brazier M, Souberbielle JC, Fournier A, Thomas T.

Nephrol Dial Transplant. 2003 Sep;18(9):1882-90.

PMID:
12937239
8.

Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.

Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A.

Nephrol Dial Transplant. 2003 Mar;18(3):582-8.

PMID:
12584283
9.

Fenofibrate increases creatininemia by increasing metabolic production of creatinine.

Hottelart C, El Esper N, Rose F, Achard JM, Fournier A.

Nephron. 2002;92(3):536-41.

PMID:
12372935
10.

Low parathyroid hormone levels and higher risk of hip fractures and mortality.

Fournier A, Oprisiu R, Mazouz H, Morinière P, El Esper N, Choukroun G.

Am J Kidney Dis. 2001 Jul;38(1):222-4. No abstract available.

PMID:
11431213
11.

[Renal osteodystrophy (3); its treatment in dialysis patients].

Ghitu S, Oprisiu R, Benamar L, Said S, Tataru Albu A, Arsenescu I, el Esper N, Morinière P, Fournier A.

Nephrologie. 2000;21(8):413-24. Review. French.

PMID:
11213385
12.

[Factors in the progression of renal insufficiency other than dyslipidemia].

Mazouz H, Kacso I, Oprisiu R, el Esper N, Makdassi R, Pruna A, Fournier A.

Nephrologie. 2000;21(7):343-4. French. No abstract available.

PMID:
11200606
13.

Sevelamer, Ca x P product and vitamin D.

Fournier A, Barsoum J, Fickl R, Oprisiu R, El Esper N, Moriniere P.

Nephrol Dial Transplant. 2001 Feb;16(2):429-30. No abstract available.

PMID:
11158431
14.

[Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].

Hottelart C, Bako G, Oprisiu R, Georgita A, Presne C, Sarraj A, Morinière P, el Esper N, Fournier A.

Nephrologie. 2000;21(6):275-82. Review. French.

PMID:
11117106
15.

[Renal osteodystrophy (1): invasive and non-invasive diagnosis of its pathologic varieties].

Oprisiu R, Hottelart C, Ghitsu S, Said S, Westeel PF, Morinière P, el Esper N, Pruna A, Fournier A.

Nephrologie. 2000;21(5):229-37. Review. French.

PMID:
11068772
16.

The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.

Fournier A, Oprisiu R, Albu AT, Dungaciu M, El Esper N, Mornière P.

Am J Kidney Dis. 2000 Jun;35(6):1248-50. No abstract available.

PMID:
10877727
17.

[Renal and hypertensive complications of extracorporeal lithotripsy].

Bataille P, Pruna A, Cardon G, Bouzernidj M, el Esper N, Ghazali A, Westeel PF, Achard JM, Fournier A.

Presse Med. 2000 Jan 15;29(1):34-8. Review. French.

PMID:
10682057
18.

Calcium antagonists and renal disease.

Fournier A, El Esper N, Pruna A, Achard JM.

Kidney Int. 1999 Dec;56(6):2311. No abstract available.

19.

Non-diabetic nephropathies and ACE inhibition.

Pruna A, El Esper N, Makdassi R, Oprisiu R, Fournie A.

Lancet. 1999 Nov 27;354(9193):1905-6. No abstract available.

PMID:
10584749
20.

Renal and hypertensive complications of extracorporeal shock wave lithotripsy: who is at risk?

Bataille P, Cardon G, Bouzernidj M, El Esper N, Pruna A, Ghazali A, Westeel PF, Achard JM, Fournier A.

Urol Int. 1999;62(4):195-200. Review.

PMID:
10567881
21.

Risk factors of renal failure progression two years prior to dialysis.

Mazouz H, Kacso I, Ghazali A, El Esper N, Moriniere P, Makdassi R, Hardy P, Westeel PF, Achard JM, Pruna A, Fournier A.

Clin Nephrol. 1999 Jun;51(6):355-66.

PMID:
10404696
22.

Importance of vitamin D repletion in uraemia.

Fournier A, Fardellone P, Achard JM, Ghazali A, Pruna A, El Esper N, Morinière P.

Nephrol Dial Transplant. 1999 Apr;14(4):819-23. Review. No abstract available.

PMID:
10328449
23.

[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].

Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A.

Nephrologie. 1999;20(1):41-4. French.

PMID:
10081035
24.

[Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].

Kacso I, Gherman M, Mazouz H, Ghazali A, el Esper N, Morinière P, Makdassi R, Hardy P, Westeel PF, Achard JM, Pruna A, Fournier A.

Nephrologie. 1999;20(1):19-28. Review. French.

PMID:
10081033
25.

[Idiopathic calcium lithiasis. Practical guide for dietary measures prescriptions].

Achard JM, Bataille P, Hottelart C, Pruna A, Ghazali A, Oprisiu R, Rumpala C, el Esper N, Fournier A.

Presse Med. 1998 Feb 7;27(5):230-7. Review. French. No abstract available. Erratum in: Presse Med 1998 Mar 7;27(9):415.

PMID:
9768019
26.

Renal osteodystrophy in dialysis patients: diagnosis and treatment.

Fournier A, Oprisiu R, Hottelart C, Yverneau PH, Ghazali A, Atik A, Hedri H, Said S, Sechet A, Rasolombololona M, Abighanem O, Sarraj A, El Esper N, Moriniere P, Boudailliez B, Westeel PF, Achard JM, Pruna A.

Artif Organs. 1998 Jul;22(7):530-57. Review.

PMID:
9684690
27.

Percutaneous recanalization of occlusion of central and proximal veins in chronic hemodialysis. Technical note.

Morinière P, Rodary-Vautier R, Fillioux-Morfaux V, Dehouck B, el Esper N, Remond A, Fournier A.

Kidney Int. 1997 Nov;52(5):1406-11.

28.

Is oral intermittent calcitriol more effective than daily calcitriol therapy in suppressing overt secondary hyperparathyroidism in predialysis patients?

Fournier A, Oprisiu R, el Esper N, Morinière P.

Nephrol Dial Transplant. 1997 Feb;12(2):365-7. No abstract available.

PMID:
9132669
29.

Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients?

Fournier A, Oprisiu R, Moriniere P, El Esper N.

Nephrol Dial Transplant. 1996 Jul;11(7):1493-5. No abstract available.

PMID:
8815432
30.

Optimal plasma concentrations of intact parathyroid hormone in predialysis patients.

Fournier A, Oprisiu R, El Esper N, Morinière Ph.

Nephrol Dial Transplant. 1995 Dec;10(12):2376-8. No abstract available.

PMID:
8808254
31.

[Hypertension and pregnancy. Diagnosis, physiopathology and treatment].

Fournier A, Fievet P, el Esper I, el Esper N, Vaillant P, Gondry J.

Schweiz Med Wochenschr. 1995 Nov 25;125(47):2273-98. Review. French.

PMID:
8539576
32.

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.

Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.

Nephron. 1995;71(3):254-83. Review.

PMID:
8569975
33.

[Vitamin D treatment and renal osteodystrophy: indications and modalities].

Fournier A, Morinière P, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.

Nephrologie. 1995;16(2):165-90. Review. French.

PMID:
7753302
34.

Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.

Aparicio M, Dratwa M, el Esper N, Fillastre JP, Levaltier B, Lins R, Meyrier A, Mignon F, Ryckelynck JP, Sennesael J.

Am J Cardiol. 1994 Dec 22;74(13):43A-50A.

PMID:
7998585
35.

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.

Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM, et al.

BMJ. 1994 Oct 1;309(6958):833-7.

36.

Hypertension and progression of renal insufficiency.

Fournier A, el Esper N, Makdassi R, Hué P, Westeel PF, Achard JM, Lalau JD.

Nephrol Dial Transplant. 1994;9 Suppl 3:28-34. Review.

PMID:
8072721
37.

[Long-term development of Permacath Quinton catheters used as a vascular access route for extra-renal detoxification].

Dupont D, Morinière P, Pourchez T, el Esper N, Fournier A.

Nephrologie. 1994;15(2):105-10. French.

PMID:
8047192
38.

Management of hyperphosphatemia in patients with renal failure.

Ghazali A, Ben Hamida F, Bouzernidj M, el Esper N, Westeel PF, Fournier A.

Curr Opin Nephrol Hypertens. 1993 Jul;2(4):566-79. Review.

PMID:
7859019
39.

Calcium metabolism, plasma parathyroid hormone, and calcitriol in transient hypertension of pregnancy.

Lalau JD, Jans I, el Esper N, Bouillon R, Fournier A.

Am J Hypertens. 1993 Jun;6(6 Pt 1):522-7.

PMID:
8343236
40.

Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.

Moriniere P, el Esper N, Viron B, Judith D, Bourgeon B, Farquet C, Gheerbrant J, Chapuy M, Van Orshoven A, Pamphile R, et al.

Kidney Int Suppl. 1993 Jun;41:S121-4.

PMID:
8320904
41.

Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.

Morinière P, Djerad M, Boudailliez B, el Esper N, Boitte F, Westeel PF, Compagnon M, Brazier M, Achard JM, Fournier A.

Nephron. 1992;60(1):6-11.

PMID:
1738415
42.

Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.

Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R, et al.

Nephron. 1992;60(2):154-63.

PMID:
1552999
43.

[Vertebral density of hypercalciuric lithiasis. Its relation to calcium-protein intake and vitamin D metabolism].

Lalau JD, Achard JM, Bataille P, Bergot C, Jans I, Boudailliez B, Petit J, Henon G, Westeel PF, el Esper N, et al.

Ann Med Interne (Paris). 1992;143(5):293-8. French.

PMID:
1482031
44.

Atrial natriuretic factor in pregnancy and pregnancy-induced hypertension.

Fournier A, Gregoire I, el Esper N, Lalau JD, Westeel PF, Makdassi R, Fievet P, de Bold AJ.

Can J Physiol Pharmacol. 1991 Oct;69(10):1601-8. Review.

PMID:
1838028
45.

Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers.

Bataille P, Achard JM, Fournier A, Boudailliez B, Westeel PF, el Esper N, Bergot C, Jans I, Lalau JD, Petit J, et al.

Kidney Int. 1991 Jun;39(6):1193-205.

46.

Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis.

Morinière P, Marie A, el Esper N, Fardellone P, Deramond H, Remond A, Sebert JL, Fournier A.

Nephron. 1991;59(4):654-7.

PMID:
1766508
47.

[Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].

Djerad M, Morinière P, Westeel PF, el Esper N, Boitte F, Morsli R, Schenouda M, Compagnon M, Achard JM, Fournier A.

Nephrologie. 1991;12(4):193-7. French.

PMID:
1745337
48.

[Increase of the pressor response to angiotensin II in normal pregnancy. A sign of increasing blood volume more than decreasing vascular reactivity].

el Esper N, Gregoire I, Fievet P, Westeel PF, Gondry J, Lalau JD, Fournier A.

Arch Mal Coeur Vaiss. 1990 Jul;83(8):1099-102. French.

PMID:
2124447
49.

[Physiopathology of idiopathic calcium lithiasis].

Bataille P, Fournier A, el Esper N, Westeel PF.

Nephrologie. 1990;11(1):29-42. Review. French.

PMID:
2197570
50.

Plasma atrial natriuretic factor and urinary excretion of a ouabain displacing factor and dopamine in normotensive pregnant women before and after delivery.

Gregoire I, el Esper N, Gondry J, Boitte F, Fievet P, Makdassi R, Westeel PF, Lalau JD, Favre H, de Bold A, et al.

Am J Obstet Gynecol. 1990 Jan;162(1):71-6.

PMID:
2154103

Supplemental Content

Loading ...
Support Center